Ramelteon

Melatonin Receptor Agonist — NERVOUS SYSTEM

Key facts

Ramelteon is an ofp drug in the Melatonin Receptor Agonist class catalogued in DrugCentral. It was first approved by the FDA in 2005. Its mechanism of action is classified as Melatonin Receptor Agonists. DrugCentral lists 3 molecular targets, including MTNR1A, MTNR1B and SIGMAR1. Recorded indications include Initial insomnia.

• Approval status: ofp (first approved 2005 by the FDA).
• Drug class: Melatonin Receptor Agonist.
• Mechanism of action: Melatonin Receptor Agonists.
• Molecular targets: MTNR1A, MTNR1B and SIGMAR1 (3 listed in DrugCentral).
• Indications: Initial insomnia.
• ATC code: N05CH02 (Melatonin receptor agonists).
• Molecular formula: C16H21NO2; molecular weight 259.35 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Initial insomnia

Contraindications (8)

• Alcoholism
• Depressive disorder
• Disease of liver
• Hepatic failure
• Hyperprolactinemia
• Sleep apnea
• Sleep automatism
• Suicidal thoughts

Mechanism & targets

• Mechanism of action (MoA): Melatonin Receptor Agonists
• Established pharmacologic class: Melatonin Receptor Agonist

Molecular targets (3)

Target	Gene	Action	Activity
Melatonin receptor type 1A	MTNR1A	agonist	Ki 10.90
Melatonin receptor type 1B	MTNR1B	agonist	Ki 10.39
Sigma non-opioid intracellular receptor 1	SIGMAR1	unknown	Ki 5.05

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2005-07-22	FDA	—	TAKEDA PHARMS USA

ATC classification

ATC code	Therapeutic hierarchy
N05CH02	NERVOUS SYSTEM › PSYCHOLEPTICS › HYPNOTICS AND SEDATIVES › Melatonin receptor agonists

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Abnormal dreams	216.0
Nightmare	196.3
Initial insomnia	196.3
Somnolence	195.7
Middle insomnia	169.3
Pneumonia aspiration	112.5
Hepatic function abnormal	109.2
Hangover	101.8
Poor quality sleep	99.9
Altered state of consciousness	94.6
Product dispensing error	78.0
Restlessness	76.2

Chemical structure

• Molecular formula: C₁₆H₂₁NO₂
• Molecular weight: 259.35 g/mol
• CAS number: 196597-26-9
• InChIKey: YLXDSYKOBKBWJQ-LBPRGKRZSA-N
• PubChem CID: 208902

CCC(=O)NCC[C@@H]1CCC2=C1C1=C(OCC1)C=C2

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Ramelteon used for?

DrugCentral lists the following indications for Ramelteon: Initial insomnia.

How does Ramelteon work?

Ramelteon is classified as Melatonin Receptor Agonists; its molecular targets in DrugCentral include MTNR1A (agonist), MTNR1B (agonist) and SIGMAR1.

When was Ramelteon first approved?

Ramelteon was first approved by the FDA in 2005.

What drug class does Ramelteon belong to?

Ramelteon is in the Melatonin Receptor Agonist class.

What is the chemical formula of Ramelteon?

Ramelteon has the molecular formula C16H21NO2 and a molecular weight of 259.35 g/mol.

Sources

• DrugCentral drug card 2355 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1218 — compound record and bioactivity
• PubChem CID 208902 — chemical identifiers
• DrugBank DB00980 — drug record
• FDA UNII 901AS54I69 — substance identity
• DailyMed: FDA labels for Ramelteon — current prescribing information (label search)
• UniProt P48039 (MTNR1A) — target protein
• UniProt P49286 (MTNR1B) — target protein
• UniProt Q99720 (SIGMAR1) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.